Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $714.99 | 12 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Vector Surgical, LLC | $300.11 | 1 | $0 (2024) |
| Bard Peripheral Vascular, Inc. | $113.37 | 1 | $0 (2020) |
| Focal Therapeutics, Inc. | $79.53 | 1 | $0 (2017) |
| Merck Sharp & Dohme LLC | $60.04 | 2 | $0 (2024) |
| SpringWorks Therapeutics, Inc. | $27.14 | 1 | $0 (2024) |
| Lilly USA, LLC | $26.57 | 1 | $0 (2024) |
| Janssen Biotech, Inc. | $26.26 | 1 | $0 (2024) |
| Genmab U.S., Inc. | $26.01 | 1 | $0 (2024) |
| Stemline Therapeutics Inc. | $23.02 | 1 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $16.65 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $522.09 | 10 | Vector Surgical, LLC ($300.11) |
| 2020 | $113.37 | 1 | Bard Peripheral Vascular, Inc. ($113.37) |
| 2017 | $79.53 | 1 | Focal Therapeutics, Inc. ($79.53) |
All Payment Transactions
12 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $26.26 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $16.65 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $16.29 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $26.63 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $33.41 | General |
| Category: ONCOLOGY | ||||||
| 10/08/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $23.02 | General |
| Category: Oncology | ||||||
| 09/17/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $27.14 | General |
| Category: DESMOID TUMORS | ||||||
| 04/13/2024 | Vector Surgical, LLC | — | Food and Beverage | Cash or cash equivalent | $300.11 | General |
| 04/01/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $26.01 | General |
| Category: Oncology | ||||||
| 02/21/2024 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $26.57 | General |
| Category: Oncology | ||||||
| 02/10/2020 | Bard Peripheral Vascular, Inc. | — | Food and Beverage | In-kind items and services | $113.37 | General |
| Category: BD Interventional - Peripheral Intervention | ||||||
| 08/28/2017 | Focal Therapeutics, Inc. | BioZorb (Device) | Food and Beverage | In-kind items and services | $79.53 | General |
| Category: Tissue Marker | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 760 | 898 | $273,729 | $105,395 |
| 2022 | 8 | 473 | 558 | $198,638 | $76,629 |
| 2021 | 9 | 248 | 266 | $130,980 | $39,406 |
| 2020 | 13 | 820 | 991 | $440,118 | $145,602 |
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 19301 | Partial removal of breast | Facility | 2023 | 58 | 60 | $75,119 | $30,184 | 40.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 238 | 323 | $50,278 | $20,294 | 40.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 117 | 166 | $37,092 | $15,114 | 40.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 88 | 88 | $27,016 | $10,805 | 40.0% |
| 19083 | Biopsy of breast and placement of locating device using ultrasound, first growth | Office | 2023 | 22 | 22 | $23,298 | $8,592 | 36.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 98 | 98 | $19,992 | $7,852 | 39.3% |
| 38525 | Biopsy or removal of deep lymph nodes of underarm | Facility | 2023 | 26 | 26 | $21,749 | $4,506 | 20.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 21 | 23 | $7,386 | $3,175 | 43.0% |
| 38900 | Imaging of lymph nodes during surgery | Facility | 2023 | 20 | 20 | $5,187 | $2,146 | 41.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 12 | 12 | $4,872 | $2,032 | 41.7% |
| 76098 | X-ray of surgical specimen | Facility | 2023 | 60 | 60 | $1,740 | $695.43 | 40.0% |
| 19301 | Partial removal of breast | Facility | 2022 | 43 | 44 | $53,152 | $22,058 | 41.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 84 | 126 | $29,862 | $11,964 | 40.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 122 | 164 | $27,388 | $10,989 | 40.1% |
| 19083 | Biopsy of breast and placement of locating device using ultrasound, first growth | Office | 2022 | 25 | 25 | $26,475 | $10,148 | 38.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 81 | 81 | $24,867 | $10,104 | 40.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 81 | 81 | $16,524 | $5,966 | 36.1% |
| 38525 | Biopsy or removal of deep lymph nodes of underarm | Facility | 2022 | 20 | 20 | $16,120 | $3,559 | 22.1% |
| 38900 | Imaging of lymph nodes during surgery | Facility | 2022 | 17 | 17 | $4,250 | $1,841 | 43.3% |
| 19301 | Partial removal of breast | Facility | 2021 | 20 | 22 | $34,436 | $11,203 | 32.5% |
| 19303 | Total removal of breast | Facility | 2021 | 11 | 11 | $26,924 | $8,559 | 31.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 34 | 34 | $11,230 | $4,502 | 40.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 33 | 42 | $11,178 | $4,137 | 37.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 71 | 78 | $17,712 | $4,033 | 22.8% |
| 38525 | Biopsy or removal of lymph nodes of under the arm, open procedure | Facility | 2021 | 14 | 14 | $15,112 | $2,563 | 17.0% |
About Dr. Lanette Smith, MD
Dr. Lanette Smith, MD is a Surgery healthcare provider based in Tulsa, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1306951637.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lanette Smith, MD has received a total of $714.99 in payments from pharmaceutical and medical device companies, with $522.09 received in 2024. These payments were reported across 12 transactions from 11 companies. The most common payment nature is "Food and Beverage" ($714.99).
As a Medicare-enrolled provider, Smith has provided services to 2,301 Medicare beneficiaries, totaling 2,713 services with total Medicare billing of $367,032. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Practice Information
- Specialty Surgery
- Location Tulsa, OK
- Active Since 08/19/2006
- Last Updated 04/27/2011
- Taxonomy Code 208600000X
- Entity Type Individual
- NPI Number 1306951637
Products in Payments
- BioZorb (Device) $79.53
- KEYTRUDA (Biological) $60.04
- OGSIVEO (Drug) $27.14
- VERZENIO (Drug) $26.57
- RYBREVANT (Drug) $26.26
- Tivdak (Drug) $26.01
- Orserdu (Drug) $23.02
- SCEMBLIX (Drug) $16.65
- Lenvima (Drug) $16.29
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Surgery Doctors in Tulsa
Dr. Craig Johnson, M.d, M.D
Surgery — Payments: $1.3M
Eugene Dickens, M.d, M.D
Surgery — Payments: $624,128
William Jennings, Md, MD
Surgery — Payments: $411,101
Bryce Murray, Md, MD
Surgery — Payments: $148,514
Dr. Gregory Pittman, M.d, M.D
Surgery — Payments: $103,994
Steven Feher, M.d, M.D
Surgery — Payments: $62,720